Pituitary Metastasis and Clinical Management

Pituitary metastasis represents a rare but clinically significant manifestation of systemic malignancy, most frequently arising from breast and lung primaries. Lesions may present with nonspecific symptoms such as headache, visual impairment owing to optic chiasm compression, cranial nerve palsies, anterior hypopituitarism and, less commonly, diabetes insipidus. Diagnosis relies on high-resolution magnetic resonance imaging with contrast enhancement, complemented by dedicated endocrine testing to characterise hormonal deficits. Multimodal management requires close collaboration between endocrinologists, neurosurgeons, oncologists and radiation specialists. Surgical debulking via a transsphenoidal route may relieve mass effect and establish histological diagnosis, while radiotherapy and systemic therapies—ranging from conventional chemotherapy to targeted agents—aim to control residual disease and improve quality of life. Advances in molecular profiling and imaging have refined diagnostic accuracy and enabled personalised treatment strategies, although overall prognosis remains guarded, with median survival measured in months. Ongoing research continues to elucidate optimal sequencing of interventions and to explore novel agents capable of crossing the blood–brain barrier.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pituitary Metastasis and Clinical Management publication trend

The graph below shows the total number of articles in pituitary metastasis and clinical management across all publications each year (not limited to Nature Index journals).

Technical terms

Hypopituitarism: Deficiency of one or more hormones produced by the anterior pituitary gland, leading to metabolic and endocrine dysfunction.

Diabetes insipidus: Disorder caused by inadequate secretion or action of antidiuretic hormone, resulting in excessive dilute urine output and thirst.

Transsphenoidal surgery: Minimally invasive surgical approach accessing the pituitary gland via the sphenoid sinus to remove sellar lesions.

BRAF inhibitor: Targeted therapy designed to block aberrant BRAF kinase activity in tumour cells harbouring activating mutations, thereby inhibiting tumour growth.

References

1. Pituitary metastases: presentation and outcomes from a pituitary center over the last decade. Pituitary (2020).
2. Pituitary metastases from neuroendocrine neoplasms: case report and narrative review. Pituitary (2021).
3. A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy. Frontiers in Endocrinology (2020).